Combined lung carcinoma

Summary

Combined lung carcinoma (MONDO:0006167) is a cancer. A subtype of neuroendocrine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	combined lung carcinoma
Mondo ID	MONDO:0006167
EFO	EFO:1000200
NCIT	C7591
UMLS	C1333123
MedGen	234166
GARD	0024316
Is cancer (heuristic)	yes

Also known as: combined carcinoma of lung · combined carcinoma of the lung · combined lung cancer · combined lung carcinoma

Disease family

This is a subtype of neuroendocrine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › combined lung carcinoma

Related subtypes (11): small cell carcinoma, anal canal neuroendocrine neoplasm, large cell neuroendocrine carcinoma, pancreatic endocrine carcinoma, malignant adrenal gland pheochromocytoma, liver neuroendocrine carcinoma, medullary thyroid gland carcinoma, goblet cell carcinoma, cutaneous neuroendocrine carcinoma, thymic neuroendocrine carcinoma, vulvar neuroendocrine carcinoma

Subtypes (2): combined small cell lung carcinoma, lung combined large cell neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.